High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
暂无分享,去创建一个
R. Fanin | M. Tiribelli | D. Raspadori | D. Damiani | M. Bocchia | A. Geromin | E. Simeone | Margherita Cavallin | S. Sirianni
[1] S. Aref,et al. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma , 2017, Hematological oncology.
[2] Jian-yong Li,et al. Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia , 2016, Oncotarget.
[3] R. Fanin,et al. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors , 2015, Oncotarget.
[4] Daoxin Ma,et al. The Profile of T Helper Subsets in Bone Marrow Microenvironment Is Distinct for Different Stages of Acute Myeloid Leukemia Patients and Chemotherapy Partly Ameliorates These Variations , 2015, PloS one.
[5] A. Burnett,et al. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse , 2015, Leukemia.
[6] H. Dombret,et al. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis , 2014, British journal of haematology.
[7] J. Esteve,et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. , 2013, Blood.
[8] Ø. Bruserud,et al. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. , 2012, European cytokine network.
[9] W. Tse,et al. Th17 related cytokines in acute myeloid leukemia. , 2012, Frontiers in bioscience.
[10] L. Meyaard,et al. CD200R signaling in tumor tolerance and inflammation: A tricky balance. , 2012, Current opinion in immunology.
[11] R. Hills,et al. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells , 2012, Leukemia.
[12] R. Hills,et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function , 2012, Leukemia.
[13] P. Hari,et al. CD200 expression in plasma cell myeloma , 2011, British journal of haematology.
[14] Ash A. Alizadeh,et al. CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.
[15] R. Fanin,et al. Two novel NPM1 mutations in a therapy‐responder AML patient , 2009, Hematological oncology.
[16] T. Whiteside,et al. Increased Frequency and Suppression by Regulatory T Cells in Patients with Acute Myelogenous Leukemia , 2009, Clinical Cancer Research.
[17] M. Hallek,et al. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. , 2009, Leukemia research.
[18] C. Tato,et al. Alternative lifestyles of T cells , 2008, Nature Immunology.
[19] W. Farrar,et al. Cancer stem cells, CD200 and immunoevasion. , 2008, Trends in immunology.
[20] R. Hills,et al. CD200 as a prognostic factor in acute myeloid leukaemia , 2007, Leukemia.
[21] T. Rème,et al. CD200 is a new prognostic factor in multiple myeloma. , 2006, Blood.
[22] Shiang Huang,et al. Increased population of CD4+CD25high regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients , 2005, European journal of haematology.
[23] F. Mandelli,et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol , 2002, Leukemia.
[24] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[25] H. Prentice,et al. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function – implications for the adoptive immunotherapy of leukaemia , 2001, Clinical and experimental immunology.
[26] G. Mufti,et al. Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-κB, c-Myc, and pRb Pathways , 2001, The Journal of Immunology.
[27] G. Tate,et al. CD200 Expression on Plasma Cell Myeloma Cells is Associated with the Efficacies of Bortezomib, Lenalidomide and Thalidomide. , 2015, Journal of clinical and experimental hematopathology : JCEH.
[28] B. Barlogie,et al. Diagnostic usefulness and prognostic impact of CD200 expression in lymphoid malignancies and plasma cell myeloma. , 2012, American journal of clinical pathology.
[29] Bob Löwenberg,et al. Review Articles (434 articles) , 2008 .
[30] I. A. Vorob’ev,et al. [Characteristics of T-cell immunity in patients with acute leukemia]. , 2006, Terapevticheskii arkhiv.
[31] J. Kolls,et al. Interleukin 17: An example for gene therapy as a tool to study cytokine mediated regulation of hematopoiesis , 2002, Journal of cellular biochemistry. Supplement.